keyword
MENU ▼
Read by QxMD icon Read
search

ius levonorgestrel

keyword
https://www.readbyqxmd.com/read/28209488/postoperative-maintenance-levonorgestrel-releasing-intrauterine-system-and-endometrioma-recurrence-a-randomized-controlled-study
#1
Yi-Jen Chen, Teh-Fu Hsu, Ben-Shian Huang, Hsiao-Wen Tsai, Yen-Hou Chang, Peng-Hui Wang
BACKGROUND: According to three randomized trials, levonorgestrel-releasing intrauterine system significantly reduced recurrent endometriosis- related pelvic pain at postoperative year 1. Only a few studies have evaluated the long-term effectiveness of the devicefor preventing endometrioma recurrence, and the effects of a levonorgestrel-releasing intrauterine system as a maintenance therapy remain unclear. OBJECTIVES: To evaluate whether a maintenance levonorgestrel-releasing intrauterine system is effective for preventing postoperative endometrioma recurrence...
February 13, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28176932/intrauterine-levonorgestrel-delivery-with-frameless-fibrous-delivery-system-review-of-clinical-experience
#2
REVIEW
Dirk Wildemeersch, Amaury Andrade, Norman D Goldstuck, Thomas Hasskamp, Geert Jackers
The concept of using a frameless intrauterine device (IUD) instead of the conventional plastic framed IUD is not new. Frameless copper IUDs have been available since the late 1990s. They rely on an anchoring system to retain in the uterine cavity. The clinical experience with these IUDs suggests that frameless IUDs fit better as they are thin and, therefore, do not disturb or irritate the uterus. High tolerance and continuation rates have been achieved as complaints of pain are virtually nonexistent and the impact on menstrual blood loss is minimal...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28142308/a-case-of-endometrial-carcinoma-in-a-long-term-levonorgestrel-intrauterine-system-lng-52%C3%A2-mg-ius-user
#3
Melisa Thomas, Paula Briggs
This report describes a 50-year-old woman who presented to a community gynaecology clinic complaining of persistent heavy vaginal bleeding with an LNG 52 mg-IUS in situ. She was subsequently found to have stage 1 grade 1a endometrioid carcinoma. From the literature, we have identified five similar cases. This case highlights the possibility of endometrial carcinoma despite treatment with an LNG 52 mg-IUS and reinforces the importance of investigating women who present with unusual persistent or heavy vaginal bleeding...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28041992/changes-in-body-composition-in-women-using-long-acting-reversible-contraception
#4
Priscilla de Nazaré Silva Dos Santos, Tessa Madden, Karen Omvig, Jeffrey F Peipert
OBJECTIVE: Users of hormonal long-acting reversible contraception (LARC) report weight gain as a side effect, but few studies have assessed body composition change among LARC users. We evaluated weight and body composition of healthy women using the levonorgestrel intrauterine system (LNG-IUS), copper intrauterine device (copper IUD) or etonogestrel implant (ENG implant). We hypothesized that weight gain and body composition over 12 months would not differ between copper IUD, LNG-IUS and ENG implant users...
December 30, 2016: Contraception
https://www.readbyqxmd.com/read/28012273/timing-of-insertion-of-levonorgestrel-releasing-intrauterine-system-a-randomised-controlled-trial
#5
Pahh van der Heijden, Pmaj Geomini, M C Herman, S Veersema, M Y Bongers
OBJECTIVE: The objective was to assess whether patient-perceived pain during the insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) depends on the timing during the menstrual cycle. DESIGN: A stratified two-armed non-inferiority randomised controlled trial. SETTING: Large teaching hospital in Veldhoven, the Netherlands. SAMPLE: From October 2013 to May 2014, 60 nulliparous and 60 multiparous women were randomised...
January 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27990196/levonorgestrel-releasing-intrauterine-system-52-mg-for-idiopathic-heavy-menstrual-bleeding-a-health-technology-assessment
#6
(no author information available yet)
BACKGROUND: Heavy menstrual bleeding affects as many as one in three women and has negative physical, economic, and psychosocial impacts including activity limitations and reduced quality of life. The goal of treatment is to make menstruation manageable, and options include medical therapy or surgery such as endometrial ablation or hysterectomy. This review examined the evidence of effectiveness and cost-effectiveness of the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) as a treatment alternative for idiopathic heavy menstrual bleeding...
2016: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/27984850/development-of-endometrioid-adenocarcinoma-despite-levonorgestrel-releasing-intrauterine-system-a-case-report-with-discussion-and-review-of-the-rcog-bsge-guideline-on-the-management-of-endometrial-hyperplasia
#7
A C L van der Meer, L S Hanna
Obesity is a significant risk factor for the development of endometrial hyperplasia and cancer. More conservative prevention and management strategies are attractive due to the increased surgical risk and complication rates associated with obesity. The Levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) has been shown to reduce the risk of developing endometrial cancer. The recent joint Green Top Guideline on the Management of Endometrial Hyperplasia published by the Royal College of Obstetricians and Gynaecologists (RCOG) with the British Society for Gynaecological Endoscopy (BSGE) recommends the LNG-IUS for the medical management of endometrial hyperplasia without atypia...
December 16, 2016: Clinical Obesity
https://www.readbyqxmd.com/read/27971668/levonorgestrel-intrauterine-system-and-norethisterone-for-the-treatment-of-chronic-abnormal-uterine-bleeding-a-randomized-clinical-comparison-in-the-patients-of-bahawalpur-pakistan
#8
M N Ashraf, G Murtaza
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970722/cost-effectiveness-analysis-of-52-mg-levonorgestrel-releasing-intrauterine-system-lng-ius-versus-short-acting-hormonal-contraceptives-in-avoiding-unintended-pregnancy-up-in-15-to-19-year-old-adolescents-under-the-brazilian-public-healthcare-system-sus
#9
A Honda, N B Ramos, M Sakagute, C Nakada, F Tobaruella
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970711/budget-impact-analysis-bia-of-the-introduction-of-52mg-levonorgestrel-releasing-intrauterine-system-lng-ius-as-a-contraceptive-method-option-in-the-brazilian-public-healthcare-system-sus-to-avoid-unintended-pregnancy-up-in-15-to-19-year-old-adolescents
#10
N B Ramos, A Honda, M Sakagute, C Nakada, F Tobaruella
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27957732/chronic-vulvovaginal-candidiasis-in-patients-using-a-levonorgestrel-containing-intrauterine-device
#11
Yvonne Nguyen, Gayle Fischer
Chronic vulvovaginal candidiasis is usually responsive to therapy with oral antifungals. We present a case series of 13 patients with this condition who were also using a levonorgestrel intrauterine system (LNG-IUS). All cases responded to ongoing oral fluconazole therapy while the LNG-IUS was in situ. The LNG-IUS was removed in six patients and of these, two experienced clinical improvement with lower fluconazole dosage requirements and three experienced complete resolution of symptoms. One remains on fluconazole 100 mg daily...
December 13, 2016: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/27940059/use-of-the-levonorgestrel-52-mg-intrauterine-system-in-adolescent-and-young-adult-solid-organ-transplant-recipients-a-case-series
#12
P S Huguelet, C Sheehan, R F Spitzer, S Scott
This case series reports on the safety and efficacy of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients. All patients used the device for contraception, with no documented cases of disseminated pelvic infection or unplanned pregnancy.
December 7, 2016: Contraception
https://www.readbyqxmd.com/read/27932442/contraceptive-sales-in-the-setting-of-the-zika-virus-epidemic
#13
Luis Bahamondes, Moazzam Ali, Ilza Monteiro, Arlete Fernandes
STUDY QUESTION: Has there been any influence of the Zika virus (ZIKV) outbreak on the sales of contraceptive methods in Brazil? SUMMARY ANSWER: Contraceptive sales in the 24 months of evaluation showed little variation and no significant change has been observed since the ZIKV outbreak. WHAT IS KNOWN ALREADY: Transmission of ZIKV is primarily by Aedes aegypti mosquitoes; however, sexual transmission has also been described. The association of several birth defects and the ZIKV infection during pregnancy has been established, and it was estimated in Bahia, Brazil that the infection rate could range from 10% to 80%...
January 2017: Human Reproduction
https://www.readbyqxmd.com/read/27930941/evaluation-of-a-new-low-dose-levonorgestrel-intrauterine-contraceptive-system-over-5-years-of-use
#14
Kristina Gemzell-Danielsson, Dan Apter, Sylvia Dermout, Thomas Faustmann, Kimberly Rosen, Thomas Schmelter, Martin Merz, Anita Nelson
OBJECTIVE: To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use. STUDY DESIGN: In this Phase III study, 2885 nulliparous and parous women aged 18-35 years were randomized to LNG-IUS 8 or LNG-IUS 12 for 3 years. After 3 years, women using LNG-IUS 12 could continue for up to 2 additional years (5 years total). The primary outcome was occurrence of pregnancy (Pearl Index). Secondary outcomes included safety, bleeding, dysmenorrhea, discontinuations, and user satisfaction...
November 20, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27928678/usage-of-the-levonorgestrel-releasing-intrauterine-system-lng-ius-in-adolescence-what-is-the-evidence-so-far
#15
REVIEW
Magdalini Patseadou, Lina Michala
PURPOSE: The levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective method of contraception, while also providing various non-contraceptive benefits. Although targeted primarily to adults, there is increasing experience in its use in adolescence. The aim of this review is to assess the available information on LNG-IUS usage in adolescence. METHODS: We conducted an online search on MEDLINE and SCOPUS from inception to May 24, 2015. All studies that examined LNG-IUS use in teen populations were eligible for inclusion...
December 7, 2016: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/27913230/effects-of-combined-oral-contraceptives-depot-medroxyprogesterone-acetate-and-the-levonorgestrel-releasing-intrauterine-system-on-the-vaginal-microbiome
#16
J Paul Brooks, David J Edwards, Diana L Blithe, Jennifer M Fettweis, Myrna G Serrano, Nihar U Sheth, Jerome F Strauss, Gregory A Buck, Kimberly K Jefferson
OBJECTIVES: Prior studies suggest that the composition of the vaginal microbiome may positively or negatively affect susceptibility to sexually transmitted infections (STIs) and bacterial vaginosis (BV). Some female hormonal contraceptive methods also appear to positively or negatively influence STI transmission and BV. Therefore, changes in the vaginal microbiome that are associated with different contraceptive methods may explain, in part, effects on STI transmission and BV. STUDY DESIGN: We performed a retrospective study of 16S rRNA gene survey data of vaginal samples from a subset of participants from the Human Vaginal Microbiome Project at Virginia Commonwealth University...
November 29, 2016: Contraception
https://www.readbyqxmd.com/read/27913229/a-single-arm-phase-iii-study-exploring-the-efficacy-and-safety-of-lng-ius-8-a-low-dose-levonorgestrel-intrauterine-contraceptive-system-total-content-13-5-mg-in-an-asia-pacific-population
#17
Guangsheng Fan, Sukho Kang, Mulan Ren, Edith Weisberg, Eeva Lukkari-Lax, Katrin Roth, SoYoung Shin
OBJECTIVE: The objective was to evaluate the efficacy and safety of a low-dose levonorgestrel intrauterine system with total content 13.5 mg (average approximately 8 μg/24 h over the first year; LNG-IUS 8; Jaydess®) in an Asia-Pacific population. STUDY DESIGN: An open-label, single-arm phase III study conducted at 25 centers in China, Australia and Korea assessed LNG-IUS 8 use over 3 years in nulliparous and parous women (N=1114) aged 18-40 years with regular menstrual cycles (21-35 days)...
November 29, 2016: Contraception
https://www.readbyqxmd.com/read/27901412/oral-progestogens-versus-levonorgestrel-releasing-intrauterine-system-for-treatment-of-endometrial-intraepithelial-neoplasia
#18
Mary L Marnach, Kristina A Butler, Michael R Henry, Catherine E Hutz, Carrie L Langstraat, Christine M Lohse, Petra M Casey
BACKGROUND: Limited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN. METHODS: We retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS...
November 30, 2016: Journal of Women's Health
https://www.readbyqxmd.com/read/27896507/levonorgestrel-releasing-intrauterine-systems-versus-oral-cyclic-medroxyprogesterone-acetate-in-endometrial-hyperplasia-therapy-a-meta-analysis
#19
Jin-Sung Yuk, Jae Yen Song, Jung Hun Lee, Won I Park, Hyeong Sik Ahn, Hyun Jung Kim
BACKGROUND: This study aimed to compare the levonorgestrel-releasing intrauterine system (LNG-IUS) with oral cyclic medroxyprogesterone acetate (MPA) in endometrial hyperplasia therapy using randomized controlled trials (RCTs). METHODS: The study searched MEDLINE, EMBASE, CENTRAL, and other databases. All regression outcomes were calculated for dichotomous outcomes in terms of relative risk (RR) and 95% confidence intervals (CIs) using a Mantel-Haenszel random effects model...
November 28, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27884916/usual-medical-treatments-or-levonorgestrel-ius-for-women-with-heavy-menstrual-bleeding-long-term-randomised-pragmatic-trial-in-primary-care
#20
Joe Kai, Lee Middleton, Jane Daniels, Helen Pattison, Konstantinos Tryposkiadis, Janesh Gupta
BACKGROUND: Heavy menstrual bleeding (HMB) is a common, chronic problem affecting women and health services. However, long-term evidence on treatment in primary care is lacking. AIM: To assess the effectiveness of commencing the levonorgestrel-releasing intrauterine system (LNG-IUS) or usual medical treatments for women presenting with HMB in general practice. DESIGN AND SETTING: A pragmatic, multicentre, parallel, open-label, long term, randomised controlled trial in 63 primary care practices across the English Midlands...
December 2016: British Journal of General Practice: the Journal of the Royal College of General Practitioners
keyword
keyword
70416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"